Breast and Cervical Cancer Early Detection Program to Expand

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.

WASHINGTON--For the first time since its inception in 1991, fundsfrom the Breast and Cervical Cancer Early Detection Program willflow to all 50 states in fiscal 1997, the Department of Healthand Human Services announced.

In addition to the 50 states and the District of Columbia, fundsfor the education and screening effort will go to three territories--theNorthern Mariana Islands, the Republic of Palau, and the VirginIslands--and 13 American Indian and Alaska Native organizations.

The CDC program serves low-income and minority women. From itsbeginning through May 1996, it has provided 457,600 mammogramsto women--2,495 of whom were diagnosed with breast cancer--and612,000 Pap tests, which found cervical intraepithelial neoplasiain 19,166 women and invasive cancer in 239.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Related Content